18F-FDG PET/CT and 99mTc-TRODAT Scan Findings in the Variants of Progressive Supranuclear Palsy and Correlation With Clinical Findings

Aim: The aim of this study is to elucidate the patterns of characteristic hypometabolism on 18F-Fluoro Deoxy-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in the variants of Progressive supranuclear palsy (PSP) and its correlation with their core clinical features. Material and Methods: A retrospective analysis of 88 subjects with clinically suspected PSP was done. An institutional informed consent to participate in the study was taken from all the subjects. All the subjects had undergone a prior 99mTechnetium labeled Tropane derivative of dopamine transporter Single Photon Emission Computed Tomography (99mTc TRODAT-1 SPECT) study and had abnormal scans to confirm degenerative parkinsonism. The subjects were clinically examined by the neurologists using the Progressive Supranuclear Palsy Rating Scale proposed by the Movement Disorder Society and were further clinically segregated into eight subtypes. All the included subjects further underwent a detailed clinical analysis to obtain their individual Schwab and England activities of daily living scale and Modified Hoehn and Yahr staging by a neurologist. All the subjects underwent 18F-FDG PET/CT scan after adequate preparation. The scans were analyzed both qualitatively (visually) and quantitatively using Statistical Parametric Mapping. Results: The frontal, limbic, and sensorimotor cortices represented the common areas of hypometabolism among all the subtypes of PSP. The subcortical regions showing the most significant hypometabolism were the thalami, mid-brain, nucleus accumbens, caudate, globus pallidus, and putamen in descending order. Multiple cortical and subcortical regions of hypometabolism were identified in different subtypes of PSP. Conclusion: The characteristic patterns of hypometabolism observed in the different subgroups were more apparent on quantification and based on visual analysis alone, it may not be possible to differentiate the different subtypes of PSP. A good correlation was seen between some of the core clinical features and hypometabolic clusters.

[1]  Rene L. Utianski,et al.  Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants , 2019, NeuroImage: Clinical.

[2]  J. Grafman,et al.  FDG-PET patterns associated with underlying pathology in corticobasal syndrome , 2019, Neurology.

[3]  Rene L. Utianski,et al.  Prosodic and phonetic subtypes of primary progressive apraxia of speech , 2018, Brain and Language.

[4]  Gerta Rücker,et al.  18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment , 2017, The Journal of Nuclear Medicine.

[5]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[6]  Isabella Castiglioni,et al.  The utility of FDG-PET in the differential diagnosis of Parkinsonism , 2017, Neurological research.

[7]  Nikolaus R. McFarland,et al.  Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[8]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 2014, Seminars in Neurology.

[9]  V. Dhawan,et al.  Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography , 2013, Neuroradiology.

[10]  C. Jack,et al.  Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid , 2012, European journal of neurology.

[11]  S. Krafczyk,et al.  Postural imbalance and falls in PSP correlate with functional pathology of the thalamus , 2011, Neurology.

[12]  John R Hodges,et al.  Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  Christina Elfgren,et al.  Selective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractography , 2011, BMC neurology.

[14]  K. Leenders,et al.  Typical cerebral metabolic patterns in neurodegenerative brain diseases , 2010, Movement disorders : official journal of the Movement Disorder Society.

[15]  R. Bressan,et al.  Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1 , 2010, Journal of the Neurological Sciences.

[16]  Chris C. Tang,et al.  Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis , 2010, The Lancet Neurology.

[17]  D. Eidelberg.  Metabolic brain networks in neurodegenerative disorders: a functional imaging approach , 2009, Trends in Neurosciences.

[18]  D. Eidelberg,et al.  Abnormal metabolic networks in atypical parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[19]  K. Jellinger.  Different Tau Pathology Pattern in Two Clinical Phenotypes of Progressive Supranuclear Palsy , 2008, Neurodegenerative Diseases.

[20]  H. Golan,et al.  [Nuclear neuroimaging of dopamine transporter in Parkinsonism--role in routine clinical practice]. , 2007, Harefuah.

[21]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[22]  이필휴.  A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies , 2007 .

[23]  C. Jack,et al.  Rates of cerebral atrophy in autopsy‐confirmed progressive supranuclear palsy , 2006, Annals of neurology.

[24]  B. Boeve,et al.  Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome , 2005, Movement disorders : official journal of the Movement Disorder Society.

[25]  B. Choe,et al.  Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. , 2004, European journal of radiology.

[26]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[27]  Yi-Hsin Weng,et al.  Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  G K Wenning,et al.  Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  S. Wey,et al.  Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  T. Yen,et al.  Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[32]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.